Evidence map›Paper›PMID 38571355›Full record

ArticleCurrent pharmaceutical design2024

Survival of Patients with Primary Brain Tumor: A Data Analysis of 10 Years.

Shristy Verma, Rishabha Malviya, Prerna Uniyal

Abstract readEditorial
PubMed Publisher
In one paragraph

Article in Current pharmaceutical design, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Shristy VermaDepartment of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, U.P., India.
Rishabha MalviyaDepartment of Pharmacy, School of Medical and Allied Sciences, Galgotias University, Greater Noida, U.P., India.ORCID 0000-0003-2874-6149
Prerna UniyalSchool of Pharmacy, Graphic Era Hill University, Dehradun, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe prognosis for primary brain tumors, like other CNS tumors, can vary greatly based on several factors, such as treatment history, age and gender at diagnosis, ethnic background, and treatment plan. MATERIALS AND

methodsA systematic review approach was used to gather relevant data from PubMed, ScienceDirect, Google Scholar, and other sources.

resultsThe survival rate of primary brain tumors and other CNS tumors appears to be correlated with several variables, including treatment history, gender, age at evaluation, race/ethnicity, and treatment regimen; this emphasizes the importance of routinely updating epidemiological data on primary brain tumors to advance biological understanding.

conclusionThis study draws attention to the variations in the median survival times of the various kinds of primary brain tumors, with oligodendroglioma having the longest median survival time (199 months, or approximately 16.6 years) and glioblastoma having the shortest (8 months).

Indexed as

Brain NeoplasmsData AnalysisGlioblastomaHumansPrognosisSurvival Ratedeath rateglioblastomaglobal trendprimary brain tumorsurvival rate.Survival rate

Identifiers

PMID38571355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.